Indegene Limited — Earnings Release 2026

Oct 30, 2025

==> picture [77 x 73] intentionally omitted <==

INDGN/SE/2025-26/73

October 30, 2025

BSE Limited,Phiroze Jeejeebhoy Towers,Dalal Street,Mumbai- 400001, India.Scrip Code: 544172	National Stock Exchange of India LimitedExchange Plaza, C-1, Block G,Bandra Kurla Complex, Bandra (E),Mumbai – 400 051, India.Trading symbol: INDGN

Dear Sir / Madam,

Sub: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the copy of Press Release dated October 30, 2025, titled “Indegene Continues Strong Momentum with 17% YoY Revenue Growth, Expands Capabilities Through Two Strategic Acquisitions”.

Kindly take the same on records.

Thanking you,

Yours Sincerely,

For Indegene Limited

Srishti Digitally signed by Ramesh Srishti Ramesh Kaushik Date: 2025.10.30 Kaushik 20:47:36 +05'30'

Srishti Ramesh Kaushik Company Secretary and Compliance Officer

Encl: As above

==> picture [132 x 41] intentionally omitted <==

Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy

Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777 www.indegene.com

CIN: L73100KA1998PLC102040

==> picture [49 x 36] intentionally omitted <==

==> picture [15 x 64] intentionally omitted <==

Press release

Indegene Continues Strong Momentum with 17% YoY Revenue Growth, Expands Capabilities Through Two Strategic Acquisitions

Bengaluru, India, October 30, 2025: Indegene, the tech-native, life sciences specialist, announced its financial results for the quarter ended September 30, 2025.

• Achieved revenue of INR 8,042 million, reflecting 17% growth YoY & 5.7% growth QoQ

• Maintained a strong profitability profile, with an adjusted EBITDA margin of 18.2% and a PAT margin of 12.7%

• Announced two acquisitions: (i) BioPharm, a US-based specialized marketing services agency (part of the Omnicom Health Group) with deep expertise in omnichannel strategy, end-to-end media journey, and hyper-targeted HCP engagement solutions, and, (ii) WARN & CO., a UK-based transformation consulting firm with a proven track record in helping global organizations design and transition to new operating models, systems, and ways of working

==> picture [371 x 166] intentionally omitted <==

----- Start of picture text ----- Quarter endedSI.No. Particulars Sep 30, Jun 30, Sep 30,2025 2025 20241. Revenue from operations 8,042 7,608 6,8682. Revenue from operations ($ Mn) 92.2 88.9 82.03. YoY revenue growth from operations (%) 17.1% 12.5% 8.0%4. Adjusted EBITDA [(1)] 1,461 1,543 1,2675. Adjusted EBITDA margin [(1)] (%) 18.2% 20.3% 18.4%6. Profit after tax 1,021 1,164 9177. Profit margin (%) 12.7% 15.3% 13.4%----- End of picture text -----

(1) Adjusted EBITDA excluding M&A-related expenses, which are non-recurring / non-operational

Last month, the company hosted the 7[th] edition of the Indegene Digital Summit (IDS) 2025 in Philadelphia, US. IDS is the flagship thought leadership platform for the life sciences industry, facilitating dialogue among senior executives, regulators, and digital innovators.

“We delivered strong growth for the fourth consecutive quarter, driven by continued momentum in deal wins and execution. A robust pipeline generation points to a positive industry outlook. In the next quarter, our focus will be on renewals and new wins to build a solid foundation for the next calendar year,” said Manish Gupta, Chairman and CEO, Indegene. “Further, I am excited to welcome BioPharm and WARN & Co. to the Indegene family. Both bring strong growth flywheels and advanced capabilities that align with our vision and future direction.”

“In Q2FY26, our focus was on executing our strategic priorities: from business development - to build a stronger pipeline; to delivery - especially on newer engagement models like Tectonic; from technology enablement - to bring AI to clients faster; to M&A - to deepen our expertise & credibility”, said Suhas Prabhu, CFO, Indegene. “We are encouraged by the progress made on each of these fronts, and expect to see tangible benefits from these initiatives in the near term.”

==> picture [49 x 36] intentionally omitted <==

==> picture [15 x 64] intentionally omitted <==

About Indegene

Indegene Limited (BSE: 544172, NSE: INDGN) is the tech-native, life sciences specialist orchestrating the path from commercialization strategy through execution. Trusted by the world’s top 20 biopharma companies across the value chain - from clinical and medical through commercial - Indegene helps life sciences leaders move at the speed of their ambition with #PractitionerLevelConfidence. Indegene’s difference comes from integrating deep domain knowledge, contextualized technology and operational excellence, built over 25 years. When bold life sciences leaders want to take breakthrough therapies to market faster, maximize impact, and create seamless experiences for patients and physicians, they count on Indegene. Orchestrate your path at www.indegene.com

For Investor inquiries, please contact: IR@Indegene.com

For media inquiries, please contact: Yadunandan K V | yadunandan.kv@indegene.com